Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Beta-ureidopropionase deficiency is a very rare pyrimidine metabolism disorder described in fewer than 10 patients to date with an extremely wide clinical picture ranging from asymptomatic cases to neurological (epilepsy, autism) and developmental disorders (urogenital, colorectal).
Features include always present findings: Elevated circulating N-carbamyl-beta-aminoisobutyric acid concentration, Elevated urinary ureidopropionic acid level, and Reduced hepatic beta-ureidopropionase activity; and common findings: Global developmental delay. 27 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 6 | Abnormal speech pattern, Dystonia, Seizure |
UPB1 function has not been fully characterized.
Beta-ureidopropionase deficiency is associated with mutations in the UPB1 gene on chromosome 22.
Genetic testing for UPB1 is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 3 always present features, 1 common feature.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
1 clinical trial registered, 1 recruiting. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.
3 publications have been identified in PubMed for beta-ureidopropionase deficiency. Research spans Epidemiology / Natural History (67%) and Case Report / Case Series (33%).
Ferrera G (2026). [PMID: 42082260](https://pubmed.ncbi.nlm.nih.gov/42082260/). *BMJ Case Rep*. [Case Report / Case Series]
Yu K (2025). [PMID: 40422899](https://pubmed.ncbi.nlm.nih.gov/40422899/). *Metabolites*. [Epidemiology / Natural History]
Xiao Z (2025). [PMID: 39960968](https://pubmed.ncbi.nlm.nih.gov/39960968/). *Medicine*. [Epidemiology / Natural History]
Data assembled from 7 of 12 sources · Last updated Sep 19, 2026, 1:04 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Lab test results |
3 |
Elevated circulating N-carbamyl-beta-aminoisobutyric acid concentration, Increased circulating lactate concentration, Elevated circulating N-carbamoyl-beta-alanine concentration |
Kidneys and urinary system | 3 | Elevated urinary ureidopropionic acid level, Elevated urinary N-carbamyl-beta-aminoisobutyric acid level, Elevated urinary ureidoisobutyric acid level |
Muscles | 2 | Low muscle tone (hypotonia), Neonatal hypotonia |
Metabolism | 1 | Metabolic acidosis |
Digestive system | 1 | Reduced hepatic beta-ureidopropionase activity |
Head and neck | 1 | Microcephaly |
Bones and joints | 1 | Sideways curvature of the spine (scoliosis) |
Pregnancy and birth | 1 | Neonatal hypotonia |